← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oncternal Therapeutics, Inc.
San Diego, CA
$4,057,241
Total funding
3
Grants
Funding over time
peak $1.2M · FY2021–24$2M$1.5M$1M$500K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$4,057,241 · 3
By mechanism
R44$3,759,570 · 2
R41$297,671 · 1
Investigators at Oncternal Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development$1,023,231
R44 · FY2022 · CA
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease$1,007,034
R44 · FY2024 · NS
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development$925,560
R44 · FY2021 · CA
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease$753,745
R44 · FY2023 · NS
Selective Androgen Receptor Degraders (SARDs) as new therapeutics for spinal and bulbar muscular atrophy (SBMA)$297,671
R41 · FY2021 · NS
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as New Potential Therapeutic for Kennedy's Disease$50,000
R44 · FY2024 · NS